AptarGroup Inc (ATR)
Aptar’s Nasal Vaccine Delivery Solutions Featured in CastleVax Phase II Clinical Trial of an Intranasal COVID-19 Vaccine Candidate
Aptar’s Nasal Vaccine Delivery Solutions Featured in CastleVax Phase II Clinical Trial of an Intranasal COVID-19 Vaccine Candidate
📈 **POSITIVE** • Medium confidence analysis (78%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business